See more : Globalworth Real Estate Investments Limited (GWI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fintech Ecosystem Development Corp. (FEXDR) Income Statement Analysis – Financial Results
- Sembcorp Marine Ltd (SMBMF) Income Statement Analysis – Financial Results
- Rubius Therapeutics, Inc. (RUBY) Income Statement Analysis – Financial Results
- ANZ Group Holdings Limited (ANZ.NZ) Income Statement Analysis – Financial Results
- Charles Stanley Group PLC (CAY.L) Income Statement Analysis – Financial Results
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.50M | 2.61M | 133.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 45.21M | 28.32M | 16.01M | 6.13M | 9.01M | 1.15M | 1.00K | 183.20M | 1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 389.04M | 335.01M | 335.40M | 264.90M | 94.71M | 50.35M | 2.61M | -183.07M | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.59% | 92.21% | 95.44% | 97.74% | 91.31% | 97.77% | 99.96% | -137,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 648.45M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M | 114.74M | 45.97M | 27.83M | 12.64M | 4.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 309.80M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M | 33.00M | 10.81M | 4.45M | 3.34M | 1.84M |
| Other Expenses | 0.00 | 9.51M | 241.00K | 7.65M | 12.45M | 3.95M | 10.60M | 2.17M | -200.00K | -3.02M | -3.01M | -350.00K | -22.00K |
| Operating Expenses | 958.25M | 983.93M | 717.14M | 595.02M | 518.88M | 421.72M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Cost & Expenses | 1.00B | 1.01B | 733.14M | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M | 147.74M | 56.78M | 32.28M | 15.99M | 6.56M |
| Interest Income | 26.69M | 11.07M | 1.93M | 7.04M | 13.24M | 9.54M | 4.07M | 3.79M | 2.32M | 608.00K | 216.00K | 1.00K | 4.00K |
| Interest Expense | 66.00M | 43.02M | 29.42M | 33.29M | 1.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K |
| Depreciation & Amortization | 26.01M | 18.20M | 13.24M | 12.26M | 8.54M | 19.54M | 5.83M | 3.42M | 1.38M | 684.00K | 444.00K | 313.00K | 34.00K |
| EBITDA | -516.45M | -640.51M | -410.32M | -139.81M | -389.77M | -177.56M | -312.51M | -244.58M | -146.35M | -56.09M | -34.63M | -16.02M | -6.55M |
| EBITDA Ratio | -118.93% | -175.99% | -108.56% | -118.98% | -396.98% | -1,051.94% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -569.21M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M | -147.74M | -56.78M | -32.28M | -15.99M | -6.56M |
| Operating Income Ratio | -131.08% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12,593.49% | -186,471.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.26M | -52.81M | -71.24M | 144.76M | 24.73M | 174.28M | 10.60M | 2.17M | 2.12M | -3.02M | -2.79M | -349.00K | -288.00K |
| Income Before Tax | -608.46M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Income Before Tax Ratio | -140.12% | -193.14% | -128.91% | -68.39% | -385.14% | -382.75% | -12,187.52% | -184,841.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.83M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K | -2.32M | -684.00K | -3.01M | -350.00K | 248.00K |
| Net Income | -606.64M | -707.42M | -454.03M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M | -145.62M | -59.80M | -35.07M | -16.33M | -6.85M |
| Net Income Ratio | -139.70% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11,567.34% | -184,867.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| EPS Diluted | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 | -1.21 | -0.71 | -0.30 |
| Weighted Avg Shares Out | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
| Weighted Avg Shares Out (Dil) | 73.54M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 29.06M | 23.06M | 23.06M |
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports